While targeted therapies have emerged in the past decade to improve treatment of non-small cell lung cancer (NSCLC) with some types of driver mutations (such as EGFR and ALK), lung adenocarcinomas with KRAS driver mutations have been notoriously difficult to study and treat.

Drs. Upal Basu Roy, Amy Moore, and Dhru Deb discuss their recent publication in which they presented an analysis of the lung cancer drug pipeline. They talk about what it means for patients, new drugs under development for NSCLC and SCLC, and some of the ongoing challenges and opportunities this rapid growth means for the lung cancer community.

LUNGevity's Amy Moore, PhD, sits down with Mark Awad, MD, PhD, a thoracic oncologist at Dana-Farber Cancer Institute, to discuss KRAS-positive lung cancer and what questions newly diagnosed patients should ask their doctors. We discuss first-line treatment, biomarker testing, clinical trials, and drug resistance.

On May 28, 2021, the United States Food & Drug Administration (FDA) approved sotorasib as the first targeted therapy for patients with KRAS G12C-positive non-small cell lung cancer (NSCLC). Both researchers and patients celebrated this historic breakthrough, which had been a goal since the KRAS oncogene was discovered 40 years ago. KRAS is a leading driver mutation in various forms of cancer.

Upal Basu Roy, PhD, MPH, LUNGevity's Executive Director of Research, interviews Patrick Forde, MD (MB, BCH), at the 2022 AACR meeting about his findings on immunotherapy in early-stage lung cancer.

On January 31, 2022,  Amy Moore, PhD, brought us an update on KRAS. Dr. Moore, LUNGevity's Vice President of Global Engagement and Patient Partnerships, spoke with Terri Conneran, KRAS lung cancer survivor and founder of the KRAS Kickers; and Darryl McConnell, PhD, Research Site Head at Boehringer Ingelheim in Vienna, Austria.